当前位置:首页 - 行情中心 - 皓宸医疗(002622) - 财务分析 - 利润表

皓宸医疗

(002622)

  

流通市值:19.57亿  总市值:19.57亿
流通股本:8.40亿   总股本:8.40亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入523,639,966.97313,632,742.87129,643,591.18500,650,216.76
营业收入523,639,966.97313,632,742.87129,643,591.18500,650,216.76
二、营业总成本520,216,907.68328,515,500.63138,688,928.62637,102,817
营业成本261,977,888.47164,232,283.1570,318,835.04292,943,752.91
税金及附加1,709,862.491,256,576.38540,454.422,614,851.19
销售费用110,269,851.9668,158,068.2927,209,509.77129,953,815.96
管理费用101,846,621.3466,164,369.1531,677,083.31132,794,804.44
研发费用10,675,860.376,427,417.24669,850.7714,568,436.83
财务费用33,736,823.0522,276,786.428,273,195.3164,227,155.67
其中:利息费用27,578,026.8917,577,589.795,960,665.7162,598,575.95
其中:利息收入1,554,731.62288,755.979,998.641,846,742.08
加:公允价值变动收益---66,394,323.9
加:投资收益24,302,264.420,010,711.473,961,736.4110,587,783.26
资产处置收益2,857,599.892,857,599.89-876,488.8
资产减值损失(新)387,819.71387,819.71--20,789,344.42
信用减值损失(新)-1,473,439.71-632,903.71-63,129.57-2,246,448.67
其他收益5,029,857.363,852,086.842,041,337.57,593,165.26
营业利润平衡项目0000
四、营业利润34,527,160.9411,592,556.44-3,105,393.1-74,036,632.11
加:营业外收入389,791.65282,407.46119,973.76219,406.54
减:营业外支出317,484.12271,297.04146,154.69216,127,379.69
利润总额平衡项目0000
五、利润总额34,599,468.4711,603,666.86-3,131,574.03-289,944,605.26
减:所得税费用-567,060.74-151,846.2218,510.9-9,725,300.35
六、净利润35,166,529.2111,755,513.08-3,150,084.93-280,219,304.91
持续经营净利润35,166,529.2111,755,513.08-3,150,084.93-280,219,304.91
归属于母公司股东的净利润16,321,536.97,620,553.84-707,071.25-256,788,671.99
少数股东损益18,844,992.314,134,959.24-2,443,013.68-23,430,632.92
(一)基本每股收益0.020.010-0.31
(二)稀释每股收益0.020.010-0.31
八、其他综合收益2,068,352.311,080,596.95-32,632.11-29,815,000.18
归属于母公司股东的其他综合收益2,068,352.311,080,596.95-32,632.11-29,815,000.18
九、综合收益总额37,234,881.5212,836,110.03-3,182,717.04-310,034,305.09
归属于母公司股东的综合收益总额18,389,889.218,701,150.79-739,703.36-286,603,672.17
归属于少数股东的综合收益总额18,844,992.314,134,959.24-2,443,013.68-23,430,632.92
公告日期2023-10-312023-08-312023-04-292023-04-29
审计意见(境内)标准无保留意见
TOP↑